3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:千円) |
| 前連結会計年度 (2024年3月31日) | 当連結会計年度 (2025年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 1,038,227 | 255,980 |
売掛金 | 58,332 | 2,287 |
商品 | 103,534 | 44,775 |
前渡金 | 30,084 | 129,658 |
その他 | 197,505 | 84,461 |
流動資産合計 | 1,427,684 | 517,163 |
固定資産 | | |
有形固定資産 | | |
建物(純額) | 980,937 | 594,296 |
土地 | 3,170,055 | 2,355,200 |
その他(純額) | 66,544 | 10,768 |
有形固定資産合計 | 4,217,538 | 2,960,265 |
無形固定資産 | | |
その他 | 21,258 | 2,014 |
無形固定資産合計 | 21,258 | 2,014 |
投資その他の資産 | 149,853 | 58,149 |
固定資産合計 | 4,388,649 | 3,020,429 |
資産合計 | 5,816,334 | 3,537,592 |
負債の部 | | |
流動負債 | | |
短期借入金 | 70,000 | 300,000 |
1年内返済予定の長期借入金 | 54,685 | 54,333 |
株主優待引当金 | - | 38,450 |
その他 | 411,498 | 98,967 |
流動負債合計 | 536,184 | 491,751 |
固定負債 | | |
長期借入金 | 2,347,079 | 2,293,903 |
匿名組合出資預り金 | 319 | - |
繰延税金負債 | 125,108 | 110,266 |
その他 | 12,056 | 11,135 |
固定負債合計 | 2,484,563 | 2,415,305 |
負債合計 | 3,020,747 | 2,907,056 |
純資産の部 | | |
株主資本 | | |
資本金 | 100,000 | 100,000 |
資本剰余金 | 2,939,268 | 2,939,075 |
利益剰余金 | △458,765 | △2,618,510 |
自己株式 | △1,485 | △1,530 |
株主資本合計 | 2,579,016 | 419,035 |
その他の包括利益累計額 | | |
その他有価証券評価差額金 | 276 | - |
その他の包括利益累計額合計 | 276 | - |
新株予約権 | 211,501 | 211,501 |
非支配株主持分 | 4,791 | - |
純資産合計 | 2,795,586 | 630,536 |
負債純資産合計 | 5,816,334 | 3,537,592 |
E0544337500株式会社サイトリ細胞研究所Cytori Cell Research Institute,Inc.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse375002023-03-31jppfs_cor:SubscriptionRightsToSharesMember375002023-03-31jppfs_cor:CapitalStockMember375002023-03-31jppfs_cor:CapitalSurplusMember375002023-04-012024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember375002023-04-012024-03-31jppfs_cor:SubscriptionRightsToSharesMember375002024-03-31jppfs_cor:SubscriptionRightsToSharesMember375002024-03-31jppfs_cor:CapitalStockMember375002024-03-31jppfs_cor:CapitalSurplusMember375002024-03-31jppfs_cor:RetainedEarningsMember375002024-03-31jppfs_cor:TreasuryStockMember375002025-03-31jppfs_cor:NonControllingInterestsMember375002024-04-012025-03-31jppfs_cor:NonControllingInterestsMember375002024-03-31jppfs_cor:NonControllingInterestsMember375002024-03-31jppfs_cor:ShareholdersEquityMember375002023-03-31jppfs_cor:TreasuryStockMember375002023-03-31jppfs_cor:ShareholdersEquityMember375002024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember375002024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember375002023-03-31jppfs_cor:NonControllingInterestsMember375002023-04-012024-03-31jppfs_cor:NonControllingInterestsMember375002025-05-15375002025-03-31375002024-04-012025-03-31375002024-03-31375002023-04-012024-03-31375002023-03-31375002023-03-31jppfs_cor:RetainedEarningsMember375002025-03-31jppfs_cor:ShareholdersEquityMember375002025-03-31jppfs_cor:CapitalStockMember375002025-03-31jppfs_cor:CapitalSurplusMember375002025-03-31jppfs_cor:RetainedEarningsMember375002025-03-31jppfs_cor:TreasuryStockMember375002025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember375002025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember375002025-03-31jppfs_cor:SubscriptionRightsToSharesMember375002024-04-012025-03-31jppfs_cor:ShareholdersEquityMember375002024-04-012025-03-31jppfs_cor:CapitalStockMember375002024-04-012025-03-31jppfs_cor:CapitalSurplusMember375002024-04-012025-03-31jppfs_cor:RetainedEarningsMember375002024-04-012025-03-31jppfs_cor:TreasuryStockMember375002024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember375002024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember375002024-04-012025-03-31jppfs_cor:SubscriptionRightsToSharesMember375002023-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember375002023-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember375002023-04-012024-03-31jppfs_cor:RetainedEarningsMember375002023-04-012024-03-31jppfs_cor:ShareholdersEquityMember375002023-04-012024-03-31jppfs_cor:CapitalStockMember375002023-04-012024-03-31jppfs_cor:CapitalSurplusMember375002023-04-012024-03-31jppfs_cor:TreasuryStockMember375002023-04-012024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember375002025-03-31jpcrp_cor:ReportableSegmentsMember375002025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember375002024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember375002024-04-012025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember375002024-03-31jpcrp_cor:ReportableSegmentsMember375002024-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember375002023-04-012024-03-31jpcrp_cor:ReportableSegmentsMember375002023-04-012024-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember375002025-03-31tse-acedjpfr-37500:MedicalAssetManagemetReportableSegmentsMember375002025-03-31tse-acedjpfr-37500:RealAssetManagementReportableSegmentsMember375002024-04-012025-03-31tse-acedjpfr-37500:MedicalAssetManagemetReportableSegmentsMember375002024-04-012025-03-31tse-acedjpfr-37500:RealAssetManagementReportableSegmentsMember375002024-03-31tse-acedjpfr-37500:MedicalAssetManagemetReportableSegmentsMember375002024-03-31tse-acedjpfr-37500:RealAssetManagementReportableSegmentsMember375002023-04-012024-03-31tse-acedjpfr-37500:MedicalAssetManagemetReportableSegmentsMember375002023-04-012024-03-31tse-acedjpfr-37500:RealAssetManagementReportableSegmentsMemberiso4217:JPYxbrli:pure